Breakthrough treatment for Tay-Sachs shows positive results, study finds
A UK-based American pharmaceutical firm has had positive results so far in the late-stage trials for its treatment of Tay-Sachs disease, in what could be a major breakthrough for a condition disproportionately affecting Ashkenazi Jews. Developed by IntraBio, the treatment, a drug dubbed IB1001, is being tested as a means of treating GM2 Gangliosidosis (Tay-Sachs […]
Continue Reading